Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
10th May 20197:00 amRNSPreliminary Final Results
1st May 201911:00 amRNSChanges to interests of a significant shareholder
1st May 201911:00 amRNSIntegumen Debt Conversion
8th Apr 20197:00 amRNSFinancing Update
26th Mar 20197:00 amRNSChange of Adviser
21st Jan 20194:40 pmRNSSecond Price Monitoring Extn
21st Jan 20194:35 pmRNSPrice Monitoring Extension
18th Jan 20197:00 amRNSPartnership Announcement
24th Dec 201812:36 pmRNSPrice Monitoring Extension
21st Dec 20184:29 pmRNSDirector/PDMR Shareholding
20th Dec 20185:04 pmRNSHolding(s) in Company
11th Dec 20187:00 amRNSStrategic Collaboration Agreement and Financing
8th Nov 201810:40 amRNSTrading Update and Change of Adviser
5th Oct 20183:36 pmRNSHolding(s) in Company
25th Sep 20187:00 amRNSHalf-year Report
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
30th Jul 201811:27 amRNSHolding(s) in Company
26th Jul 20185:01 pmRNSHolding(s) in Company
26th Jul 20185:00 pmRNSHolding(s) in Company
26th Jul 20183:40 pmRNSHolding(s) in Company
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
20th Jul 20183:22 pmRNSResult of General Meeting
4th Jul 20187:00 amRNSPlacing & Subscription to raise up to £0.65m
28th Jun 201811:47 amRNSResult of AGM
6th Jun 20184:55 pmRNSNotice of AGM & Posting of Annual Report&Accounts
17th May 20187:00 amRNSFinal Results
23rd Apr 20187:00 amRNSNotice of Results
21st Mar 20187:00 amRNSDirectorate Change
15th Feb 20187:00 amRNSTrading Statement
25th Jan 20187:00 amRNSChange of Adviser
23rd Jan 20187:00 amRNSAcquisition of Minority Interest
14th Sep 20175:19 pmRNSGrant of Stock Options
12th Sep 20177:00 amRNSHalf-year Report
25th Jul 20177:00 amRNSSenior Management Appointment
20th Jul 20177:00 amRNSHalf year end update
26th Apr 20176:01 pmRNSResult of AGM
25th Apr 20173:13 pmRNSProposed amendment to AGM resolution
5th Apr 20177:00 amRNSIntegumen IPO
4th Apr 20177:00 amRNSEnterprise Securities Market Notice
31st Mar 201711:26 amRNSAnnual Financial Report & Notice of AGM
29th Mar 20171:57 pmRNSIssue of Equity
22nd Mar 20177:00 amRNSFinal Results
3rd Mar 20177:00 amRNSYear End Update
18th Nov 20167:00 amRNSCompletion of Sale
10th Nov 20165:51 pmRNSREPLACEMENT - Contract win
8th Nov 20167:00 amRNSContract win
2nd Nov 20167:03 amRNSDirector/PDMR Shareholding
27th Oct 20167:00 amRNSSale of Innovenn UK Limited and Result of GM
4th Oct 20167:00 amRNSSale of Innovenn & Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.